Tessera Therapeutics
Kassi Stein is a Senior Scientist at Tessera Therapeutics since November 2021, with a background in process engineering and cellular process development. Previous roles include Scientist II at Vertex Pharmaceuticals, where Kassi developed scale-down models and implemented processing methods, and Scientist I at bluebird bio, focusing on production processes for gene therapy. Kassi earned a PhD and MS in Chemical Engineering from the Massachusetts Institute of Technology, where significant research was conducted on mitochondrial toxicity and continuous bioprocessing. Early academic and professional experiences include roles at FDA, Emirates Global Aluminium, and various research co-op positions, highlighting a strong foundation in biochemical engineering. As an advocate for STEM education, Kassi has also coordinated programs for high school students at Northeastern University.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.